MedTrace Logo

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT03692897 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1708

Last updated 2025-09-17

No results posted yet for this study

Summary

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Conditions

Interventions

OTHER

All approved therapies for the treatment of Chronic Hepatitis B (CHB)

All approved therapies for the treatment of Chronic Hepatitis B (CHB).

Sponsors & Collaborators

  • Target PharmaSolutions, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2025-09-10
Completion
2025-09-10

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03692897 on ClinicalTrials.gov